Suppr超能文献

多发性硬化症中的人类白细胞抗原(HLA)图谱提示了两种疾病形式以及保护性单倍型的存在。

HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes.

作者信息

Madigand M, Oger J J, Fauchet R, Sabouraud O, Genetet B

出版信息

J Neurol Sci. 1982 Mar;53(3):519-29. doi: 10.1016/0022-510x(82)90248-9.

Abstract

261 multiple sclerosis (MS) patients were HLA-A and -B typed and 94 were HLA-D typed. The results were compared to those of controls typed for HLA-A; HLA-B (356) and HLA-D (113). We confirm and extend earlier findings (Oger et al. 1980b) that some phenotypes could modulate the expression of the MS susceptibility gene linked to B7-DR2: DR3 was found together with DR2 in 12/94 MS and only 3/113 controls and could be marker for an "augmentor" gene. In contrast, B35 and DR1 as well as B12 and DR7 could be markers of protector genes. We compared typing results of patients subgrouped on clinical features. 61 patients with progressive evolution showed increased A1, A1-B8, B8-DR3 and A1-B8-DR3 when compared to 200 patients with remitting evolution. When compared to controls both groups showed increased B7 but only the remitting group showed increased DR2. 71 patients with "benign MS" showed increased B7-DR2 and A3-B7-DR2. 54 patients with "severe disease" showed increased DR3 and A1-B8-DR3 when compared to controls. Both groups showed increased B7 (49.2% and 44.4% versus 25.5% for controls). 120 patients treated greater than 5 years with azathioprine were divided into "no progression" and "progression" while treated. Both groups showed increased B7 when compared to controls. DR2 was increased only in the "no progression" group. B8-DR3 and A1-B8-DR3 were found increased in the "progression" group only. We conclude that two forms of MS exist with different HLA profiles.

摘要

对261例多发性硬化症(MS)患者进行了HLA - A和 - B分型,94例进行了HLA - D分型。将结果与针对HLA - A、HLA - B(356例)和HLA - D(113例)分型的对照组结果进行比较。我们证实并扩展了早期研究结果(奥热等人,1980年b),即某些表型可调节与B7 - DR2连锁的MS易感基因的表达:在94例MS患者中有12例同时发现DR3和DR2,而在113例对照组中仅有3例,DR3可能是一个“增强基因”的标志物。相比之下,B35和DR1以及B12和DR7可能是保护基因的标志物。我们比较了根据临床特征分组的患者的分型结果。与200例缓解型患者相比,61例进行性发展患者的A1、A1 - B8、B8 - DR3和A1 - B8 - DR3增加。与对照组相比,两组的B7均增加,但只有缓解型组的DR2增加。71例“良性MS”患者的B7 - DR2和A3 - B7 - DR2增加。与对照组相比,54例“重症患者”的DR3和A1 - B8 - DR3增加。两组的B7均增加(分别为49.2%和44.4%,对照组为25.5%)。120例接受硫唑嘌呤治疗超过5年的患者在治疗期间分为“无进展”和“进展”两组。与对照组相比,两组的B7均增加。仅“无进展”组的DR2增加。仅“进展”组的B8 - DR3和A1 - B8 - DR3增加。我们得出结论,存在两种具有不同HLA谱型的MS形式。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验